68results about "Antigen carriers" patented technology

Described herein are covalently modified polypeptide antigens with improved immunogenicity and / or stability, as well as compositions, cells, and methods related to the polypeptide antigens. The polypeptide antigens are covalently conjugated to one or more steroid acid moieties to improve their stability and / or to elicit improved cellular immunity or improved cellular and humoral immunity against the antigens after administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endosomal trapping of cargo by enhancing the enzymatic cleavage of endosomal membrane- ensheathed sphingomyelin to ceramide and / or endosomal escape. The steroid acid moieties can be preconjugated to a peptide, and the steroid acid-peptide moiety is subsequently conjugated to the polypeptide antigen. The peptide can comprise one or more domains that confer additional functionality to the modified polypeptide antigen.

The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and / or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

The present invention pertains to specific bioparticules at the surface of which are expressed multimeric protein. The bioparticles according to the present invention comprise an envelope consisting of a plasma membrane; and at least one type I or II transmembrane fusion protein anchored in said membrane, said fusion protein comprising successively a) a first monomer of a multimeric protein of interest, b) a coiled-coil domain or oligomerization sequence; and c) a domain for anchoring in the plasma membrane, consisting of a transmembrane segment and a cytosolic segment. Fragments a) and b) are exposed at the surface of the bioparticle, and fragment a) is bound to a second monomer of said multimeric protein by means of a bond which is not a peptide bond. The bioparticles according to the present invention can be used in therapy such as immunotherapy. The present invention also pertains to methods for producing such bioparticles.

The invention belongs to the technical field of biological medicine and disease prevention and treatment, and particularly relates to an SSEA4 conjugated virus-like particle anti-cancer vaccine as well as a preparation method and application thereof. Specifically, according to the vaccine, an SSEA4 antigen is efficiently synthesized through a chemical enzyme method, then the SSEA4 antigen is covalently coupled with a virus-like particle (VLP), the SSEA4 antigen and the VLP are combined with a monophosphoryl lipid A adjuvant with high safety, an organism can be induced to generate strong and lasting SSEA4-resistant humoral immune response, the generated antibody can specifically recognize and kill SSEA4 positive tumor cells, and the SSEA4 positive tumor cells can be effectively killed. Meanwhile, good safety is shown in an animal model, a new solution is provided for immunotherapy of SSEA4 positive tumors, and therefore the SSEA4 positive tumor immunotherapy polypeptide has wide application prospects and market value.

The present invention relates to a non-injectable drug delivery system using mucoadhesive nanoparticles, and to mucoadhesive nanoparticles and a method for producing the same, which prevent deformation of the nanoparticles due to mucosal moisture, etc., and strengthen mucoadhesiveness to prevent loss by binding a mucoadhesive polymer to the surface of the nanoparticles. The present invention also relates to a composition for maturing antigen-presenting cells, a composition for treating infectious diseases, and a composition for treating cancer, which comprise the mucoadhesive nanoparticles. The present invention also relates to mucoadhesive nanoparticles loaded with immune active substances (such as antigens and adjuvants) for cancer treatment and immunotherapy based on antigen-presenting cells including dendritic cells (DCs), and a composition for immune anti-cancer treatment comprising the same.

Methods for stabilizing a liquid vaccine for mucosal use are provided. In certain aspects, the methods may include combining a liquid comprising at least one antigen or antigen encoding composition with a petrolatum carrier.

The present disclosure generally relates to methods of identifying and / or selecting self-replicating RNA (srRNA) delivery systems suitable for biomedical applications. More particularly, the disclosure relates to methods of identifying and / or selecting srRNA delivery systems using a combination of critical quality attributes for srRNA vaccines and biotherapeutics. Also provided are srRNA compositions, formulations obtained by the methods of the disclosure, as well as methods for inducing a pharmacodynamic effect in a subject in need thereof, as well as methods for preventing and / or treating various health conditions.

Disclosed herein is a bioactive polymer for forming a solution and / or hydrogel to stabilise one or more pharmaceutically active agents prior to, during or post-administration, the polymer comprising a first monomer for binding water, a second monomer for imparting mechanical properties to the scaffold; optionally, a third monomer for binding to a natural or synthetic peptide or protein (NSPP); and a fourth monomer for imparting phase-transition behaviour. Preferably, the first monomer is OEGMA; the second monomer is PLA / HEMA; the third monomer is NAS; and the fourth monomer is NIPAAm, and the polymer comprises: OEGMA in an amount of from about 1 to about 15 mol%; PLA / HEMA in an amount of from 5 to about 50 mol%; NAS in an amount of from 0 to about 15 mol%; and NIPAAm in an amount of up to about 85 mol%.

A method of encapsulating a biomolecule in a silica shell to form a particle, the method comprising: • a) hydrolyzing a mixture of silica precursors, said mixture comprising a functionalized silica precursor comprising a Si-C bond and a non-functionalized silica alkoxide precursor, • b) directly contacting the hydrolyzed precursors with an aqueous solution comprising the biomolecule and • c) encapsulating the biomolecule in a silica shell to form a particle, such that at least a portion of the silica on the interior surface of the silica shell is functionalized and comprises a Si-C bond.

The present disclosure relates to methods of treating cancer in subjects by a two-part treatment regime comprising a first treatment that provides antigen-specific CD4+ and / or CD8+ T cells in the subject and a second treatment, administered after a time interval, that induces systemic and / or tumor-specific inflammation in the subject.

Provided is a composition for stimulating an innate immune response in a subject by a drug capable of stimulating the innate immune response in the subject (for example, damage - associated molecular pattern (DAMP) and pathogen - associated molecular pattern (PAMP)) upon administration to the subject. 【Solution means】One or more DAMPs or PAMPs, and Zn 2+ , Mn 2+ , Ca 2+ , Fe 2+ , Fe 3+ , Cu 2+ , Ni 2+ , Co 2+ , Pb 2+ , Sn 2+ , Ru 2+ , Au 2+ , Mg 2+ , VO 2+ , Al 3+ , Co 3+ , Cr 3+ , Ga 3+ , Tl 3+ , Ln 3+ , MoO 3+ , Cu + , Au + , Tl + , Ag + , Hg 2+ , Pt 2+ , Pb 2+ , Hg 2+ , Cd 2+ , Pd 2+ , Pt 4+ , Na + , and one or more cations selected from the group consisting of K + A composition is provided that includes nanoparticles containing.

A hydrogel material for use in a human subject or other mammal includes a collection of microgel particles having one or more network cross linker components, wherein the microgel particles, when exposed to an endogenous or exogenous annealing agent, links the microgel particles together in situ to form a covalently-stabilized scaffold of microgel particles having pores formed between the microgel particles wherein the pores are substantially devoid of hydrogel.

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

This application relates to methods for the production of polysaccharide antigen-carrier protein conjugates, in particular conjugates of Group B Streptococcus (GBS) capsular polysaccharide and a carrier protein, in particular CRM197. The methods comprise a hydroxyapatite chromatography step in order to separate the conjugate from free polysaccharide and free carrier protein.

The present invention relates to adenoviral vectors and uses thereof wherein the viral capsid has been coated with a polypeptide capable of stimulating a peptide-specific immune response in an individual. Furthermore, the present invention relates to methods of treating diseases, such as cancer, by means of adenoviral vectors that have been coated with polypeptides capable of eliciting a peptide-specific immune response. The invention also relates to methods of coating adenoviral vectors by specific peptides and methods of identifying those peptides suitable for coating the capsid of an adenoviral vector.

The present invention relates to the technical field of biomedicine technology and vaccines, and particularly relates to an aluminum nanocrystal delivery system with a surface covered with an Fc affinity protein and a preparation method for a self-assembled particle adjuvant vaccine. An aluminum nanocrystal is used as a carrier, the surface of the aluminum nanocrystal is covered with an Fc affinity protein molecular layer and an antigen molecule, and the antigen of a recombinant Fc Tag specifically binds to an Fc affinity protein, so that antigen self-assembly is realized, a virus-like particle vaccine is formed, and the antigen density is improved. The present vaccine can generate a high-titer specific antibody by inducing a body fluid and cell immunity.

A targeting delivery system loaded with whole-cell components, which relates to the technical field of immunotherapy. The targeting delivery system is a nano-sized or micron-sized particle with a target head on the surface, and the particle is loaded with whole-cell components of cancer cells or cancer tissues; the whole-cell components are water-soluble ingredients and water-insoluble ingredients of whole cells in cells or tissues, and the water-insoluble ingredients are dissolved by a solubilizer; and the target head binds to a molecule on the surface of a specific cell or tissue, so as to help the particle to enter the cell or tissue. According to the targeting delivery system, a specific solubilizer is used to solubilize the water-insoluble part, which allows same to be dissolved in an aqueous solution, so that the whole-cell antigens of the water-soluble ingredients and the water-insoluble ingredients in cancer cells or tissues can be combined to prepare a cancer vaccine. In addition, the target head capable of targeting antigen-presenting cells is added to improve the phagocytosis efficiency of the antigen-presenting cells in an active targeting manner, thereby improving the effect of preventing or treating cancer.

Covalently modified polypeptide antigens having improved immunogenicity and / or stability, as well as compositions, cells, and methods relating thereto, are described herein. Polypeptide antigens are covalently conjugated to a one or more of steroid acid moieties to improve their stability and / or to trigger improved cellular immunity, or improved cellular and humoral immunity, against the antigen upon administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endocytosis and / or endosomal escape of endosomally trapped cargoes by potentiating enzymatic cleavage of sphingomyelin to ceramide within endosomal membranes. The steroid acid moieties may be pre-conjugated to a peptide, and the steroid acid-peptide moiety subsequently conjugated to the polypeptide antigen. The peptide may comprise one or more domains that impart an additional functionality to the modified polypeptide antigen.

The present disclosure relates to immunostimulatory compositions that are effective in eliciting immune responses in avian species. More specifically, these immunostimulatory compositions comprise an immunomodulator composition and an immunostimulatory oligonucleotide that when administered stimulate toll-like receptor 21.

The disclosure is generally related to spherical nucleic acids (SNAs), nanostructures with a core surrounded by a radial presentation of oligonucleotides, that can target multiple classes of immune cells. Methods of making and using the nanoparticles are also provided herein. In some aspects, the disclosure provides a spherical nucleic acid (SNA) comprising: (a) a nanoparticle core; (b) a shell of oligonucleotides attached to the external surface of the nanoparticle core, the shell of oligonucleotides comprising one or more immunostimulatory oligonucleotides; and (c) a first antigen that is a major histocompatibility complex type I (MHC-I) antigen, and a second antigen that is a major histocompatibility complex type II (MHC-I I) antigen.

The invention relates to an autologous cancer vaccine and its preparation method. The autologous vaccine according to the present invention is based on hydroxyapatite and / or tricalcium phosphate particles onto which tumor proteins are adsorbed, these tumor proteins being enriched in HSP110.

This disclosure relates, in general, to methods for identifying and / or selecting self-replicating RNA (srRNA) delivery systems suitable for biomedical applications. More specifically, this disclosure relates to methods for identifying and / or selecting srRNA delivery systems using combinations of key quality characteristics for srRNA vaccines and biological products. It also provides srRNA compositions, formulations, and methods for inducing pharmacodynamic effects in subjects requiring them, as well as methods for preventing and / or treating various health conditions.

To provide monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1 with high potency, and also to provide related compositions, methods and therapeutic use.SOLUTION: Provided is an antibody or an antigen-binding fragment thereof, binding each of the following antigen complexes with a KD of ≤10 nM, as measured by a solution equilibrium titration-based assay: i) human LTBP1-precursor TGFβ1; ii) human LTBP3-precursor TGFβ1; iii) human GARP-precursor TGFβ1; and iv) human LRRC33-precursor TGFβ1, the antibody or an antigen-binding fragment thereof being a fully human or humanized antibody or fragment thereof and optionally binding with a KD of ≤1 nM.SELECTED DRAWING: None

The disclosure provides for ribozyme-mediated fusion constructs and systems and methods thereof, for use in a variety of applications, including for inducible gene expression systems, gene therapy, and combinatorial screening.

This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of TR1 cells and / or B cells in an antigen-specific manner and treating diseases and disorders in a subject in need thereof.

Disclosed herein are coronavirus (CoV) spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, as well as nanoparticles and immunogenic compositions comprising the same, which can be used to stimulate immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens that are surrounded and associated by the detergent core, resulting in enhanced stability and good immunogenicity. Doses, formulations, and methods for preparing vaccines and nanoparticles are also disclosed.

Provided in the present invention are a hepatitis B virus receptor OATP and the use thereof. Specifically, provided in the present invention is the use of a substance in the preparation of an agent for preventing and / or treating hepatitis B virus (HBV) and / or hepatitis D virus (HDV) infections in an animal or diseases related to said infections, wherein the substance prevents or reduces the interaction between HBV and / or HDV and an organic anion transporting polypeptide (OATP) in the animal, and / or prevents or reduces the expression and / or function of OATP in the animal. Further provided in the present invention are a cell model and an animal model having susceptibility to HBV and / or HDV that are obtained by means of transferring an exogenous SLCO gene into a cell or expressing an exogenous OATP protein, and a method for establishing the models; a method for delivering a drug by means of targeting OATP, and a drug delivery vehicle targeting OATP; and an OATP-targeted delivery polypeptide vehicle derived from a hepadnaviridae surface antigen.